首页> Clinical lymphoma, myeloma & leukemia> Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma.

Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma.

导出 LinkOut

翻译打印收藏纠错

第一作者： Stefan K,Barta

第一单位： Fox Chase Cancer Center, Philadelphia, PA; Montefiore Medical Center, Albert Einstein Cancer Center, Bronx, NY. Electronic address: Stefan.Barta@fccc.edu.

作者： Stefan K,Barta ^[1] ; Rishi,Jain ^[2] ; Amithaba,Mazumder ^[3] ; Jason,Carter ^[4] ; Lawrence,Almanzar ^[5] ; Roy,Browne ^[5] ; Samira,Shahnaz ^[6] ; Richard,Elkind ^[5] ; David,Kaminetzky ^[7] ; Ramakrishna,Battini ^[5] ; Olga,Derman ^[5] ; Noah,Kornblum ^[5] ; Amit,Verma ^[5] ; Ira,Braunschweig ^[5]

作者单位： Fox Chase Cancer Center, Philadelphia, PA; Montefiore Medical Center, Albert Einstein Cancer Center, Bronx, NY. Electronic address: Stefan.Barta@fccc.edu. ^[1] Fox Chase Cancer Center, Philadelphia, PA; Montefiore Medical Center, Albert Einstein Cancer Center, Bronx, NY. ^[2] NYU Clinical Cancer Institute, New York, NY; Westchester Medical Center, New York Medical College, Valhalla, NY. ^[3] Montefiore Medical Center, Albert Einstein Cancer Center, Bronx, NY; Memorial Sloan Kettering Cancer Center, New York, NY. ^[4] Montefiore Medical Center, Albert Einstein Cancer Center, Bronx, NY. ^[5] Mount Sinai Beth Israel Hospital, New York, NY. ^[6] NYU Clinical Cancer Institute, New York, NY. ^[7]

关键词 Autologous stem cell transplant High-dose chemotherapy Personalized medicine Proteasome inhibition Targeted therapy